The company’s newly-acquired funds will specifically support a new R&D facility located in Bavaria.
Drug-delivery tech developer AMW has landed $30 million from the European Union’s lending institution to help fund the company’s development activities and expand production capacity.
The German pharmaceutical company’s newly-acquired funds will specifically support a new R&D facility located in Bavaria.
The transaction was supported by the European Fund for Strategic Investments.
